To assess the efficacy and safety of PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) in managing advanced intrahepatic cholangiocarcinoma (ICC). Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.